# Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

> **NCT05495269** · PHASE2 · COMPLETED · sponsor: **Qlaris Bio, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Sturge-Weber Syndrome
- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** QLS-101 ophthalmic solution, 2.0 %

## Key facts

- **NCT ID:** NCT05495269
- **Lead sponsor:** Qlaris Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-23
- **Primary completion:** 2023-01-25
- **Final completion:** 2023-03-20
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05495269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05495269, "Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05495269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*